1. Home
  2. CFBK vs SGHT Comparison

CFBK vs SGHT Comparison

Compare CFBK & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CF Bankshares Inc.

CFBK

CF Bankshares Inc.

HOLD

Current Price

$27.80

Market Cap

184.4M

Sector

Finance

ML Signal

HOLD

Logo Sight Sciences Inc.

SGHT

Sight Sciences Inc.

HOLD

Current Price

$3.68

Market Cap

187.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CFBK
SGHT
Founded
1892
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
184.4M
187.4M
IPO Year
2005
2021

Fundamental Metrics

Financial Performance
Metric
CFBK
SGHT
Price
$27.80
$3.68
Analyst Decision
Buy
Buy
Analyst Count
1
7
Target Price
$29.00
$9.08
AVG Volume (30 Days)
41.7K
384.0K
Earning Date
05-05-2026
03-04-2026
Dividend Yield
1.30%
N/A
EPS Growth
30.58
28.16
EPS
2.69
N/A
Revenue
N/A
$77,363,000.00
Revenue This Year
$32.28
$11.81
Revenue Next Year
N/A
$10.62
P/E Ratio
$10.28
N/A
Revenue Growth
N/A
N/A
52 Week Low
$19.22
$2.03
52 Week High
$34.34
$9.24

Technical Indicators

Market Signals
Indicator
CFBK
SGHT
Relative Strength Index (RSI) 40.67 37.20
Support Level $23.49 $3.29
Resistance Level $29.95 $3.76
Average True Range (ATR) 0.69 0.20
MACD -0.05 0.08
Stochastic Oscillator 33.75 36.43

Price Performance

Historical Comparison
CFBK
SGHT

About CFBK CF Bankshares Inc.

CF Bankshares Inc is engaged in the provision of a variety of financial services. It provides personalized business banking products and services, including commercial loans and leases, commercial and residential real estate loans, equipment leasing, SBA loans and treasury management depository services. The revenues are derived principally from the interest and fees on loans originated and noninterest income generated on the sale of loans.

About SGHT Sight Sciences Inc.

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.

Share on Social Networks: